Table 3.
Multivariate analysis of long‐term HCT outcomes for ALL.
| Relapse | NRM | LFS | OS | CGRFS | Chronic GVHD | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Donor MSC (ref) | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| UD | 0.77 (0.51–1.15) | 0.2 | 1.67 (1.17–2.39) | 0.005 | 1.19 (0.91–1.55) | 0.21 | 1.34 (1–1.8) | 0.047 | 1.15 (0.9–1.46) | 0.26 | 1.22 (0.75–1.97) | 0.42 |
| Other relative | 0.89 (0.38–2.09) | 0.79 | 0.68 (0.21–2.19) | 0.52 | 0.85 (0.43–1.68) | 0.64 | 0.84 (0.39–1.83) | 0.66 | 0.91 (0.5–1.64) | 0.75 | 0.93 (0.29–3.05) | 0.91 |
| CR2/3 | 2.32 (1.54–3.47) | <0.0001 | 1.56 (1.02–2.39) | 0.04 | 1.9 (1.42–2.54) | <0.0001 | 1.78 (1.29–2.46) | 0.0004 | 1.67 (1.29–2.18) | 0.0001 | 1.26 (0.72–2.2) | 0.41 |
| Active disease | 2.53 (1.48–4.32) | 0.0007 | 1.68 (0.97–2.88) | 6.20E−02 | 2.06 (1.41–3.01) | 0.0002 | 2.02 (1.35–3.05) | 0.0007 | 1.71 (1.2–2.43) | 0.003 | 1.19 (0.54–2.59) | 0.67 |
| Age (per 10 y) | 1.03 (0.9–1.19) | 0.64 | 1.36 (1.19–1.54) | <0.0001 | 1.19 (1.08–1.31) | 0.0003 | 1.2 (1.08–1.33) | 0.0005 | 1.19 (1.09–1.29) | <0.0001 | 1.16 (0.98–1.37) | 0.083 |
| Year of HSCT | 1 (0.92–1.09) | 0.96 | 0.98 (0.91−1.06) | 0.63 | 0.99 (0.93–1.05) | 0.73 | 1.01 (0.94–1.07) | 0.85 | 0.98 (0.94–1.04) | 0.55 | 0.96 (0.87–1.06) | 0.43 |
| Diagnosis (Ref = Phineg B ALL)a | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Phipos B ALL | 1.45 (0.9–2.33) | 0.12 | 1.16 (0.73−1.84) | 0.52 | 1.28 (0.92–1.77) | 0.15 | 0.99 (0.69–1.42) | 0.96 | 1.19 (0.89–1.59) | 0.24 | 1.2 (0.66–2.19) | 0.55 |
| T ALL | 0.72 (0.42–1.23) | 0.23 | 0.82 (0.5−1.36) | 0.44 | 0.77 (0.53–1.11) | 0.16 | 0.73 (0.49–1.07) | 0.11 | 0.74 (0.54–1.03) | 0.07 | 0.67 (0.34–1.32) | 0.24 |
| Missing | 0.76 (0.47–1.24) | 0.27 | 1.13 (0.73−1.76) | 0.59 | 0.94 (0.68–1.3) | 0.7 | 0.89 (0.63–1.26) | 0.52 | 0.96 (0.72–1.28) | 0.78 | 1.19 (0.67–2.11) | 0.56 |
| RIC vs. MAC | 1.05 (0.64–1.73) | 0.84 | 0.97 (0.61–1.55) | 0.91 | 1.04 (0.74–1.47) | 0.81 | 1.06 (0.73–1.54) | 0.77 | 0.96 (0.71–1.31) | 0.8 | 0.65 (0.32–1.3) | 0.22 |
| TBI | 0.77 (0.52–1.15) | 0.2 | 1.04 (0.7–1.54) | 0.84 | 0.91 (0.69–1.2) | 0.49 | 0.94 (0.69–1.27) | 0.68 | 0.91 (0.71–1.16) | 0.44 | 0.98 (0.59–1.64) | 0.95 |
| PB vs. BM | 1.42 (0.92–2.17) | 0.11 | 1.71 (1.12–2.61) | 0.012 | 1.57 (1.16–2.12) | 0.003 | 1.54 (1.11–2.14) | 0.009 | 1.64 (1.25–2.14) | 0.0003 | 1.99 (1.14–3.48) | 0.015 |
| Female to male donor | 0.85 (0.55–1.3) | 0.45 | 1.63 (1.14–2.32) | 0.007 | 1.21 (0.93–1.59) | 0.16 | 1.23 (0.91–1.66) | 0.18 | 1.21 (0.95–1.54) | 0.12 | 1.43 (0.9–2.26) | 0.13 |
| KPS > = 90 | 1.15 (0.78–1.7) | 0.48 | 0.81 (0.58–1.12) | 0.21 | 0.94 (0.74–1.21) | 0.65 | 0.83 (0.63–1.08) | 0.16 | 0.99 (0.79–1.23) | 0.9 | 1.11 (0.69–1.77) | 0.66 |
| In vivo TCD | 1.12 (0.74–1.69) | 0.59 | 0.48 (0.33–0.69) | <0.0001 | 0.7 (0.53–0.92) | 9.00E−03 | 0.62 (0.46–0.84) | 0.002 | 0.71 (0.56–0.9) | 0.005 | 0.71 (0.44–1.15) | 0.16 |
Abbreviations: ALL, acute lymphoblastic leukemia; BM, bone marrow; CGRFS, cGVHD‐free, relapse‐free survival; CI, confidence interval; GVHD, graft‐versus‐host disease; HCT, hematopoietic cell transplantation; HR, hazard ratio; LFS, leukemia‐free survival; MAC, myeloablative conditioning; NRM, nonrelapse mortality; OS, overall survival; PB, peripheral blood; RI, relapse incidence; RIC, reduced intensity conditioning; TCD, T cell depletion.
a
As a missing category was included in the model, HR is not reliable for a type of ALL.